CO2017000552A2 - Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 - Google Patents

Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70

Info

Publication number
CO2017000552A2
CO2017000552A2 CONC2017/0000552A CO2017000552A CO2017000552A2 CO 2017000552 A2 CO2017000552 A2 CO 2017000552A2 CO 2017000552 A CO2017000552 A CO 2017000552A CO 2017000552 A2 CO2017000552 A2 CO 2017000552A2
Authority
CO
Colombia
Prior art keywords
ether groups
hsp90 inhibitors
modified ether
hsp70 inducers
biphenyl amides
Prior art date
Application number
CONC2017/0000552A
Other languages
English (en)
Inventor
S J Brian Blagg
T Rick Dobrowsky
Mercy Anyika
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of CO2017000552A2 publication Critical patent/CO2017000552A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente memoria se proporcionan compuestos de la fórmula (I) También se proporcionan composiciones farmacéuticas de los compuestos. En algunos aspectos, estos compuestos se pueden utilizar para el tratamiento de enfermedades, que incluyen la neuropatía diabética periférica o el cáncer.
CONC2017/0000552A 2014-06-24 2017-01-23 Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 CO2017000552A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016473P 2014-06-24 2014-06-24
PCT/US2015/037478 WO2015200514A2 (en) 2014-06-24 2015-06-24 Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers

Publications (1)

Publication Number Publication Date
CO2017000552A2 true CO2017000552A2 (es) 2017-04-28

Family

ID=53525293

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0000552A CO2017000552A2 (es) 2014-06-24 2017-01-23 Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70

Country Status (15)

Country Link
US (3) US10590065B2 (es)
EP (1) EP3160977A2 (es)
JP (2) JP6793640B2 (es)
KR (1) KR102536408B1 (es)
CN (1) CN106536498A (es)
AU (2) AU2015279926B2 (es)
CA (1) CA2952029A1 (es)
CL (2) CL2016003276A1 (es)
CO (1) CO2017000552A2 (es)
EA (1) EA201790070A1 (es)
IL (1) IL249712B (es)
MX (2) MX2016017133A (es)
NZ (1) NZ728482A (es)
SG (2) SG10201811574YA (es)
WO (1) WO2015200514A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2812341T3 (da) 2012-02-09 2019-11-18 Univ Kansas C-terminale hsp90-inhibitorer
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
EA201790070A1 (ru) 2014-06-24 2017-10-31 Дзе Юниверсити оф Канзас Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
CN108478568B (zh) * 2018-02-01 2020-08-28 华中农业大学 一种香豆素类化合物在制备单胺氧化酶抑制剂中的用途
CN112020506B (zh) 2018-02-07 2024-10-11 里亚塔医药公司 新生霉素类似物与脯氨酸的共晶体形式
EP3794009A1 (en) * 2018-05-14 2021-03-24 Reata Pharmaceuticals, Inc. Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
KR102175125B1 (ko) * 2018-12-28 2020-11-05 울산과학기술원 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2669687C (en) 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
US8324240B2 (en) 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5766617B2 (ja) * 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
WO2011041593A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2012008435A1 (ja) 2010-07-13 2012-01-19 大日本住友製薬株式会社 ビアリールアミド誘導体またはその薬理学的に許容される塩
WO2012138896A1 (en) 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
EP2770684B1 (en) 2011-11-16 2016-02-10 Huawei Technologies Co., Ltd. Method and device for generating microwave predistortion signal
DK2812341T3 (da) * 2012-02-09 2019-11-18 Univ Kansas C-terminale hsp90-inhibitorer
EA201790070A1 (ru) 2014-06-24 2017-10-31 Дзе Юниверсити оф Канзас Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70

Also Published As

Publication number Publication date
CA2952029A1 (en) 2015-12-30
SG10201811574YA (en) 2019-01-30
JP6793640B2 (ja) 2020-12-02
US11708319B2 (en) 2023-07-25
IL249712A0 (en) 2017-02-28
US20220041543A1 (en) 2022-02-10
CL2016003276A1 (es) 2017-05-26
US11098008B2 (en) 2021-08-24
WO2015200514A3 (en) 2016-02-25
US10590065B2 (en) 2020-03-17
AU2015279926A1 (en) 2017-02-16
JP2021042217A (ja) 2021-03-18
NZ728482A (en) 2022-11-25
EA201790070A1 (ru) 2017-10-31
JP7105851B2 (ja) 2022-07-25
US20180057446A1 (en) 2018-03-01
KR102536408B1 (ko) 2023-05-23
BR112016029672A2 (pt) 2017-08-22
WO2015200514A2 (en) 2015-12-30
MX2019015888A (es) 2020-02-07
EP3160977A2 (en) 2017-05-03
CN106536498A (zh) 2017-03-22
US20200270201A1 (en) 2020-08-27
MX2016017133A (es) 2018-01-12
AU2021200969B2 (en) 2022-08-04
AU2015279926B2 (en) 2020-12-24
KR20170035911A (ko) 2017-03-31
CL2018002367A1 (es) 2018-10-12
JP2017521496A (ja) 2017-08-03
IL249712B (en) 2021-04-29
AU2021200969A1 (en) 2021-03-11
SG11201610677XA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CO2017000552A2 (es) Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CR20150316A (es) Compuestos y sus métodos de empleo
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016001645A2 (pt) derivados de oxoquinazolinil-butanamida
NI201600070A (es) Inhibidores tetracíclicos de autotaxina